Liquid Biopsy Industry

The global Liquid Biopsy Market size was valued at USD 22.88 billion in 2030 and is expected to expand at a compound annual growth rate (CAGR) of 9.7% from 2023 to 2030. The increasing prevalence of cancer and the growing geriatric population are major drivers expected to fuel market growth. Furthermore, the use of technologically advanced devices for early detection of diseases is one of the key factors driving the market. In addition, the increasing preference for noninvasive treatment procedures will offer lucrative opportunities in the forecast period.

In recent years, cases of cancer have been rising tremendously and the trend is projected to remain the same in the foreseeable future. A significant shift in lifestyle has exposed the global population to this disorder and has resulted in oncogenic factors. For instance, as per the American Cancer Society, in 2022, the number of new cancer cases is expected to reach 1.9 million, leading to 609,360 deaths. Companies are focusing on expanding their business operations in the clinical liquid biopsy space.

For instance, in December 2021, Helio Health and Fulgent Genetics announced the launch of the former’s HelioLiver, a new liquid biopsy test for early liver cancer detection. This liquid biopsy test combines serum protein markers and cell-free DNA methylation patterns. Additionally, new research studies are aiding the development of novel liquid biopsy techniques. For instance, in July 2022, the University of Central Florida announced the development of a novel liquid biopsy technique that facilitates early detection using biomarker identification for lung and breast cancer, making the monitoring of conditions easier.

Gather more insights about the market drivers, restrains and growth of the Global Liquid Biopsy market

Liquid Biopsy Market Segments Highlights:

  • The ctDNA segment is projected to hold the largest share in the market owing to its wide use as a biomarker in the detection of cancer using liquid biopsy
  • The multi-gene-parallel analysis (NGS) technology segment is expected to grow lucratively due to increasing research and development, increasing cancer cases, advancements in technology, and strategic activities by leading companies
  • North America dominated the global market in 2022, owing to the increasing demand for new technologies, a large pool of key players, the presence of several clinical laboratories, and advanced healthcare infrastructure in the region
  • Asia Pacific is expected to grow considerably in the future, owing to the rising prevalence of target conditions in the region and the presence of key players

Liquid Biopsy Market Report Segmentation

Grand View Research has segmented the global liquid biopsy market report based on sample type, biomarker, technology, application, end-use, clinical application, product, and region:

Liquid Biopsy Sample Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Blood Sample
  • Others

Liquid Biopsy Biomarker Outlook (Revenue, USD Million, 2018 - 2030)

  • Circulating Tumor Cells (CTCs)
  • Circulating Nucleic Acids
  • Exosomes/ Microvesicles
  • Circulating Proteins

Liquid Biopsy Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Multi-gene-parallel Analysis (NGS)
  • Single Gene Analysis (PCR Microarrays)

Liquid Biopsy Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Cancer
  • Reproductive Health
  • Others

Liquid Biopsy End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals and Laboratories
  • Specialty Clinics
  • Academic and Research Centers
  • Others

Liquid Biopsy Clinical Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Therapy Selection
  • Treatment Monitoring
  • Early Cancer Screening
  • Recurrence Monitoring
  • Others

Liquid Biopsy  Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Instruments
  • Consumables Kits and Reagents
  • Software and Services

Liquid Biopsy  Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Key Liquid Biopsy Company Insights

  • ANGLE plc
  • Oncimmune Holdings PLC
  • Guardant Health
  • Myriad Genetics, Inc.
  • Biocept, Inc.
  • Lucence Health Inc.
  • Freenome Holdings, Inc.
  • Hoffmann-La Roche Ltd.
  • QIAGEN
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Epigenomics AG

Order a free sample PDF of the Liquid Biopsy Market Intelligence Study, published by Grand View Research.